IR Materials — ST PHARM

Science & Technology
- Business Overview
- CDMO
- CRO
  - AnaPath Research & Service
- R&D
  - Virtual R&D
  - Global R&D
About
Public
- PR (Public Relations)
  - News room
- IR (Investor Relations)
  - Stock Information
  - IR Library
Careers
ESG

Linkedin

Public

IR Materials

PR (Public Relations)
- News room
IR (Investor Relations)
- Stock Information
- IR Library

IR Library

[Analyst Report] Forward path clear Oct 20, 2022

[Analyst Report] OP in line on growing oligonucleotide sales Aug 11, 2022

[Presentation] ST PHARM IR Presentation (August 2022) Aug 5, 2022

[R&D Materials] STP0404 POSTER Presentation in CROI 2020 May 26, 2022

[Presentation] ST PHARM mRNA platform May 20, 2022

[Presentation] ST PHARM IR Presentation (April 2022) May 9, 2022

[Analyst Report] Focus on where it is headed, not where it is now Apr 29, 2022

[Analyst Report] Bags major oligonucleotide drug deal Mar 21, 2022

[Analyst Report] Slips to operating loss due to costs, deferred oligo sales Feb 28, 2022

[Analyst Report] Aggressive capex to cement position as global CMO Dec 2, 2021

[Analyst Report] Growing oligo sales proven to boost profits Oct 29, 2021

[Analyst Report] Developing a COVID-19 mRNA vaccine Jul 23, 2021

7of2